Markets are tanking on tariff fears, inflationary concerns and now fears of recession. "Given this is so uncertain and that ...

Sage Therapeutics (NASDAQ:SAGE) traded lower for the third straight session on Tuesday after Bank of America moved the ...

Biogen BIIB announced that dosing has begun in a phase III study evaluating its key pipeline candidate, felzartamab, in adult kidney transplant recipients diagnosed with late antibody-mediated ...

Biogen Inc. (NASDAQ:BIIB – Get Free Report) was the recipient of unusually large options trading on Monday. Stock traders purchased 32,455 put options on the company. This represents an increase of ...

Here are three reasons why BIIB doesn't excite us and a stock we'd rather own. Founded in 1978 in Switzerland as one of the ...

Jones Financial Companies Lllp boosted its holdings in Biogen Inc. (NASDAQ:BIIB – Free Report) by 37.2% in the 4th quarter, ...

Global Phase 3 TRANSCEND study will evaluate the efficacy and safety of felzartamab, as compared to placebo, in adults with late AMRAMR is a ...

High-rolling investors have positioned themselves bullish on Biogen (NASDAQ:BIIB), and it's important for retail traders to take note. \This activity came to our attention today through Benzinga's ...

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Biogen Inc (Symbol: BIIB), where a total volume of 7,265 contracts has been ...

Shares of oversold pharmaceutical giant Biogen (NASDAQ:BIIB) are up about $4.40 on the day. While we’re not seeing any specific news for the pivot higher, BIIB has become a value play.